Aida Rechdouni, MD
Pathology · Los Angeles, CANPI 1699814533
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $300 of the $459 with a category attached, or 65.3%. Cepheid accounts for 65.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $300 and has fallen 93.9% since, to $18 in 2024. Among pathology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3 payments — averaging $153.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cepheid$300
- Galderma Laboratories, L.p.$141
- BD$18
What the payments were for
- Consulting fees$30065%
- Food & beverage$15935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cepheid | 1 | $300 |
| Galderma Laboratories, L.p. | 1 | $141 |
| BD | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENEXPERT$300
How this compares
$459 in reported general payments places this provider in the 95th percentile of 467 pathology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $6,801 |
| Cyclosporine | 18 | $4,563 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $572 |
| Memantine Hcl ErMemantine Hcl | 11 | $526 |
| Azelastine Hcl | 12 | $143 |
| Pantoprazole Sodium | 11 | $35 |
| Levothyroxine Sodium | 11 | $32 |
| Trazodone Hcl | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Other pathology in Los Angeles
- Zhe PiaoLos Angeles$193
- Ashley HagiyaLos Angeles$0
- Nicole DawsonLos Angeles$0
- Sarka CernosekLos Angeles$0
- Dandan WangLos Angeles$0
- Teodulo MenesesLos Angeles$0
- Jennifer ChiaLos Angeles$0
- Jean Marie LopateguiWest Hollywood$49K
- Thomas KoniaSacramento$4K
- Kevin LuSan Francisco$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.